Back to Search
GREGORY WILDING, PHARMD
PHARMD
Pharmacist
NPI: 1619254604Individual
Specialties, Licenses & Credentials
PharmacistPrimary
Pharmacist
Code: 183500000X
6715977-1701(UT)
Research & Publications (20)
Apoptosis-related (survivin, Bcl-2), tumor suppressor gene (p53), proliferation (Ki-67), and non-receptor tyrosine kinase (Src) markers expression and correlation with clinicopathologic variables in 60 thymic neoplasms.
PMID 19318677·Chest·2009
8-other
Comparison of ACINUS, caspase-3, and TUNEL as apoptotic markers in determination of tumor growth rates of clinically localized prostate cancer using image analysis.
PMID 19644955·Prostate·2009
4-observational
Amongst eligible patients, age and comorbidity do not predict for dose-limiting toxicity from phase I chemotherapy.
PMID 19649630·Cancer Chemother Pharmacol·2010
8-other
A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors.
PMID 19434370·Invest New Drugs·2010
3-trial
Analysis of clinical and dosimetric factors associated with change in renal function in patients with gastrointestinal malignancies after chemoradiation to the abdomen.
PMID 19540051·Int J Radiat Oncol Biol Phys·2010
8-other
Development, characterization, and immunotherapeutic use of peptide mimics of the Thomsen-Friedenreich carbohydrate antigen.
PMID 19649208·Neoplasia·2009
7-preclinical
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.
PMID 19380444·J Clin Oncol·2009
3-trial
Chest tube-delivered bupivacaine improves pain and decreases opioid use after thoracoscopy.
PMID 19324125·Ann Thorac Surg·2009
2-rct
Estimation and prediction of renal function in patients with renal tumor.
PMID 19371883·J Urol·2009
8-other
Does the presence of significant risk factors affect perioperative outcomes after robot-assisted radical cystectomy?
PMID 19549262·BJU Int·2009
8-other
Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study.
PMID 19347984·J Thorac Oncol·2009
3-trial
Investigation of colonic and whole-gut transit with wireless motility capsule and radiopaque markers in constipation.
PMID 19418602·Clin Gastroenterol Hepatol·2009
4-observational
Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group.
PMID 19536901·Cancer·2009
3-trial
Acute myeloid leukemia and diabetes insipidus with monosomy 7.
PMID 19380027·Cancer Genet Cytogenet·2009
5-case
Enhanced systemic immune reactivity to a Basal cell carcinoma associated antigen following photodynamic therapy.
PMID 19549769·Clin Cancer Res·2009
4-observational
An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer.
PMID 19366825·Clin Cancer Res·2009
3-trial
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
PMID 19487381·J Clin Oncol·2009
3-trial
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
PMID 19652060·J Clin Oncol·2009
3-trial
Current status of robot-assisted surgery in urology: a multi-national survey of 297 urologic surgeons.
PMID 19671225·Can J Urol·2009
8-other
Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer.
PMID 19636017·J Clin Oncol·2009
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 420 S MAIN ST
SPRINGVILLE, UT 84663 - Phone
- (801) 853-1214
Quick Facts
- NPI
- 1619254604
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile